CR20200568A - Antcuerpos anti-cd3 y usos de estos - Google Patents
Antcuerpos anti-cd3 y usos de estosInfo
- Publication number
- CR20200568A CR20200568A CR20200568A CR20200568A CR20200568A CR 20200568 A CR20200568 A CR 20200568A CR 20200568 A CR20200568 A CR 20200568A CR 20200568 A CR20200568 A CR 20200568A CR 20200568 A CR20200568 A CR 20200568A
- Authority
- CR
- Costa Rica
- Prior art keywords
- antibodies
- relates
- present
- specifically bind
- tmeff2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862676081P | 2018-05-24 | 2018-05-24 | |
| PCT/IB2019/054188 WO2019224717A2 (en) | 2018-05-24 | 2019-05-21 | Anti-cd3 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20200568A true CR20200568A (es) | 2021-02-26 |
Family
ID=67211773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20200568A CR20200568A (es) | 2018-05-24 | 2019-05-21 | Antcuerpos anti-cd3 y usos de estos |
Country Status (38)
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| WO2018231827A1 (en) | 2017-06-12 | 2018-12-20 | Bluefin Biomedicine, Inc. | Anti-il1rap antibodies and antibody drug conjugates |
| EA202092849A1 (ru) | 2018-05-24 | 2021-03-16 | Янссен Байотек, Инк. | Моноспецифические и мультиспецифические антитела к tmeff2 и их применение |
| JOP20190116A1 (ar) * | 2018-05-24 | 2019-11-24 | Janssen Biotech Inc | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها |
| MX2020012598A (es) | 2018-05-24 | 2021-05-27 | Janssen Biotech Inc | Agentes aglutinantes del psma y usos de estos. |
| LT4324851T (lt) | 2018-07-19 | 2025-10-10 | Chimeriniai antigeno receptoriai, pasižymintys bcma specifiškumu, ir jų panaudojimas | |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| AR118720A1 (es) | 2019-04-19 | 2021-10-27 | Janssen Biotech Inc | Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3 |
| JP7686571B2 (ja) | 2019-05-08 | 2025-06-02 | ヤンセン バイオテツク，インコーポレーテツド | Ｔ細胞媒介性免疫を調節するための材料及び方法 |
| CR20220025A (es) | 2019-07-26 | 2022-05-04 | Janssen Biotech Inc | Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos |
| PH12022551470A1 (en) * | 2019-12-18 | 2023-05-03 | Janssen Biotech Inc | Materials and methods for in vivo biological targeting |
| CA3173268A1 (en) * | 2020-02-27 | 2021-09-02 | Janssen Biotech, Inc. | Materials and methods for modulating an immune response |
| US20210284731A1 (en) * | 2020-03-13 | 2021-09-16 | Janssen Biotech, Inc. | Methods and materials for modulating an immune response |
| KR20230008775A (ko) | 2020-05-08 | 2023-01-16 | 젠맵 에이/에스 | Cd3 및 cd20에 대한 이중특이적 항체 |
| PE20230389A1 (es) | 2020-05-27 | 2023-03-06 | Janssen Biotech Inc | Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas |
| JP7862361B2 (ja) | 2020-07-29 | 2026-05-19 | ヤンセン バイオテツク，インコーポレーテツド | Ｈｌａ－ｇ抗原結合ドメインを含むタンパク質及びそれらの使用 |
| JP2023539525A (ja) * | 2020-09-02 | 2023-09-14 | ジェンマブ エー／エス | 抗体療法 |
| AU2021345124A1 (en) | 2020-09-16 | 2023-03-30 | Amgen Inc. | Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer |
| WO2022068809A1 (zh) * | 2020-09-29 | 2022-04-07 | 信达生物制药(苏州)有限公司 | 抗cd3抗体以及其用途 |
| US20240025992A1 (en) | 2020-10-22 | 2024-01-25 | Janssen Biotech, Inc. | Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses |
| WO2022175255A2 (en) * | 2021-02-16 | 2022-08-25 | Janssen Pharmaceutica Nv | Trispecific antibody targeting bcma, gprc5d, and cd3 |
| MX2023013714A (es) | 2021-05-21 | 2024-01-16 | Leo Pharma As | Anticuerpos anti-proteina accesoria del receptor de interleucina 1 (il-1). |
| WO2023026235A1 (en) * | 2021-08-27 | 2023-03-02 | Janssen Biotech, Inc. | Anti-psma antibodies and uses thereof |
| US12600764B2 (en) | 2021-08-27 | 2026-04-14 | International Business Machines Corporation | Antigen-binding proteins targeting coronavirus (COV) variants |
| CN118974087A (zh) * | 2022-03-09 | 2024-11-15 | 德琪(杭州)生物有限公司 | 新颖的抗cd3抗体以及其用途 |
| WO2023178645A1 (zh) * | 2022-03-25 | 2023-09-28 | 嘉和生物药业有限公司 | 靶向cd3的抗体及其应用 |
| US12054552B2 (en) * | 2022-09-21 | 2024-08-06 | Sanofi Biotechnology | Humanized anti-IL-1R3 antibody and methods of use |
| EP4598958A1 (en) | 2022-10-05 | 2025-08-13 | Amgen Inc. | Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof |
| WO2024089551A1 (en) | 2022-10-25 | 2024-05-02 | Janssen Biotech, Inc. | Msln and cd3 binding agents and methods of use thereof |
| WO2024126833A1 (en) * | 2022-12-16 | 2024-06-20 | Ichnos Sciences SA | Cd47-il1rap bispecific antibodies |
| WO2025134050A1 (en) | 2023-12-21 | 2025-06-26 | Janssen Biotech, Inc | Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma |
| WO2025134049A1 (en) | 2023-12-21 | 2025-06-26 | Janssen Biotech, Inc | Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis |
| TW202602940A (zh) | 2024-04-09 | 2026-01-16 | 美商安進公司 | 激動性抗ｉｌ－２ｒｂｇ重鏈抗體 |
| WO2025230233A1 (ko) * | 2024-05-03 | 2025-11-06 | 국민대학교산학협력단 | 인간 cd3에 특이적인 항체 및 이의 용도 |
| WO2025259563A2 (en) * | 2024-06-10 | 2025-12-18 | Amberstone Biosciences, Inc. | Anti-cd3 constructs and uses thereof |
| WO2026006492A2 (en) | 2024-06-25 | 2026-01-02 | Ypsilon Therapeutics, Inc. | Anti-prame/hla-a2 antibodies and uses thereof |
| WO2026006495A1 (en) | 2024-06-25 | 2026-01-02 | Alloy Therapeutics, Inc. | Anti-wt1/hla-a2 antibody and uses thereof |
| WO2026078647A1 (en) | 2024-10-11 | 2026-04-16 | Janssen Biotech, Inc. | Combination of trispecific antibody targeting bcma, gprc5d and cd3, and pomalidomide for the treatment of multiple myeloma |
| US20260102490A1 (en) | 2024-10-11 | 2026-04-16 | Janssen Biotech, Inc. | Combination of trispecific antibody targeting bcma, gprc5d and cd3, and an anti-cd38 antibody for the treatment of multiple myeloma |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| ES2243007T3 (es) | 1997-09-16 | 2005-11-16 | Egea Biosciences Llc | Sintesis quimica completa y sintesis de genes de genomas. |
| US6670127B2 (en) | 1997-09-16 | 2003-12-30 | Egea Biosciences, Inc. | Method for assembly of a polynucleotide encoding a target polypeptide |
| US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| DK1999154T3 (da) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | Fremstillede heterodimere proteindomæner |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| CN101952312A (zh) | 2007-07-31 | 2011-01-19 | 米迪缪尼有限公司 | 多特异性表位结合蛋白及其应用 |
| US8748356B2 (en) | 2007-10-19 | 2014-06-10 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
| AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| JP2012505654A (ja) | 2008-10-14 | 2012-03-08 | ヤンセン バイオテツク，インコーポレーテツド | 抗体をヒト化及び親和性成熟する方法 |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| WO2012162067A2 (en) | 2011-05-21 | 2012-11-29 | Macrogenics, Inc. | Cd3-binding molecules capable of binding to human and non-human cd3 |
| US9574010B2 (en) | 2011-11-04 | 2017-02-21 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| WO2014093908A2 (en) | 2012-12-14 | 2014-06-19 | Omt, Inc. | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same |
| KR102813816B1 (ko) * | 2013-07-05 | 2025-05-29 | 젠맵 에이/에스 | 인간화 또는 키메라 cd3 항체 |
| HUE050159T2 (hu) * | 2013-12-17 | 2020-11-30 | Genentech Inc | Anti-CD3 antitestek és alkalmazási eljárások |
| CN106459201A (zh) * | 2014-05-28 | 2017-02-22 | 豪夫迈·罗氏有限公司 | 结合人和食蟹猴CD3ε的抗体 |
| EP2982693A1 (en) | 2014-08-07 | 2016-02-10 | Affimed Therapeutics AG | CD3 binding domain |
| AR103488A1 (es) * | 2015-01-23 | 2017-05-10 | Sanofi Sa | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 |
| BR112018008908A2 (pt) | 2015-11-02 | 2018-11-27 | Janssen Pharmaceutica Nv | anticorpos anti-il1rap, moléculas de ligação ao antígeno biespecíficas que se ligam il1rap e cd3, e seus usos |
| CR20220578A (es) | 2016-09-14 | 2023-01-17 | Teneobio Inc | Anticuerpos de unión a cd3 |
| WO2019220368A1 (en) * | 2018-05-16 | 2019-11-21 | Janssen Biotech, Inc. | Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy |
| MX2020012598A (es) | 2018-05-24 | 2021-05-27 | Janssen Biotech Inc | Agentes aglutinantes del psma y usos de estos. |
| EA202092849A1 (ru) | 2018-05-24 | 2021-03-16 | Янссен Байотек, Инк. | Моноспецифические и мультиспецифические антитела к tmeff2 и их применение |
| JOP20190116A1 (ar) | 2018-05-24 | 2019-11-24 | Janssen Biotech Inc | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها |
-
2019
- 2019-05-21 BR BR112020023508-3A patent/BR112020023508A2/pt unknown
- 2019-05-21 RS RS20250579A patent/RS66901B1/sr unknown
- 2019-05-21 CN CN202510209510.8A patent/CN120058941A/zh active Pending
- 2019-05-21 UA UAA202008271A patent/UA129050C2/uk unknown
- 2019-05-21 JO JOP/2020/0302A patent/JOP20200302A1/ar unknown
- 2019-05-21 DK DK19737219.6T patent/DK3802608T3/da active
- 2019-05-21 WO PCT/IB2019/054188 patent/WO2019224717A2/en not_active Ceased
- 2019-05-21 ES ES19737219T patent/ES3032856T3/es active Active
- 2019-05-21 PE PE2020001886A patent/PE20210132A1/es unknown
- 2019-05-21 SM SM20250221T patent/SMT202500221T1/it unknown
- 2019-05-21 FI FIEP19737219.6T patent/FI3802608T3/fi active
- 2019-05-21 EA EA202092847A patent/EA202092847A1/ru unknown
- 2019-05-21 CR CR20200568A patent/CR20200568A/es unknown
- 2019-05-21 MX MX2020012587A patent/MX420253B/es unknown
- 2019-05-21 US US16/418,082 patent/US11603405B2/en active Active
- 2019-05-21 HR HRP20250621TT patent/HRP20250621T1/hr unknown
- 2019-05-21 PL PL19737219.6T patent/PL3802608T3/pl unknown
- 2019-05-21 CN CN201980049271.7A patent/CN112912397B/zh active Active
- 2019-05-21 LT LTEPPCT/IB2019/054188T patent/LT3802608T/lt unknown
- 2019-05-21 PT PT197372196T patent/PT3802608T/pt unknown
- 2019-05-21 SG SG11202011270QA patent/SG11202011270QA/en unknown
- 2019-05-21 EP EP19737219.6A patent/EP3802608B1/en active Active
- 2019-05-21 CA CA3101271A patent/CA3101271A1/en active Pending
- 2019-05-21 AU AU2019274656A patent/AU2019274656B2/en active Active
- 2019-05-21 JP JP2020565282A patent/JP7530299B2/ja active Active
- 2019-05-21 HU HUE19737219A patent/HUE072251T2/hu unknown
- 2019-05-21 KR KR1020207037046A patent/KR20210012007A/ko active Pending
- 2019-05-21 EP EP25173398.6A patent/EP4643951A3/en active Pending
- 2019-05-21 SI SI201930938T patent/SI3802608T1/sl unknown
- 2019-05-21 MA MA52773A patent/MA52773B1/fr unknown
- 2019-05-24 UY UY0001038245A patent/UY38245A/es unknown
- 2019-05-24 AR ARP190101400A patent/AR115422A1/es unknown
-
2020
- 2020-11-09 PH PH12020551920A patent/PH12020551920A1/en unknown
- 2020-11-19 IL IL278846A patent/IL278846A/en unknown
- 2020-11-23 NI NI202000089A patent/NI202000089A/es unknown
- 2020-11-23 CL CL2020003033A patent/CL2020003033A1/es unknown
- 2020-11-23 EC ECSENADI202075215A patent/ECSP20075215A/es unknown
- 2020-11-23 CO CONC2020/0014506A patent/CO2020014506A2/es unknown
- 2020-11-24 SA SA520420631A patent/SA520420631B1/ar unknown
- 2020-12-18 ZA ZA2020/07936A patent/ZA202007936B/en unknown
-
2023
- 2023-03-08 US US18/180,225 patent/US20230322924A1/en active Granted
-
2024
- 2024-05-29 JP JP2024087232A patent/JP2024116190A/ja not_active Withdrawn
-
2026
- 2026-06-18 AU AU2026204725A patent/AU2026204725A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020003033A1 (es) | Anticuerpos anti-cd3 y usos de estos. | |
| ECSP20082991A (es) | Agentes aglutinantes del psma y usos de estos | |
| ES3063317T3 (en) | Humanized or chimeric cd3 antibodies | |
| CO2021001893A2 (es) | Anticuerpos anti-gdf15, composiciones y métodos de uso | |
| CY1124384T1 (el) | Κατασκευες διπλοειδικων αντισωματων που δεσμευονται σε egfrviii και cd3 | |
| CO2018003436A2 (es) | Anticuerpos agonistas que se unen específicamente a cd40 humana y métodos de uso | |
| ECSP19086810A (es) | Anticuerpos que se unen específicamente a pd-1 y métodos de uso | |
| ECSP18041833A (es) | Anticuerpos que se unen específicamente a pd-1 y sus usos | |
| CO2018011364A2 (es) | Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos | |
| EA201891582A1 (ru) | Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки | |
| CL2019000799A1 (es) | Anticuerpos y fragmentos de los mismos que se unen al receptor cannabinoide 1 (cb1) humano. (divisional solicitud 201602433) | |
| CU24533B1 (es) | Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos | |
| CO2020014343A2 (es) | Anticuerpos específicos para cd3 y sus usos | |
| BR112016000666A2 (pt) | Constructos de ligação de antígeno cd3 e cd19 biespecíficos | |
| AR106555A1 (es) | Anticuerpos anti-il1rap, moléculas de unión a antígenos biespecíficas que se unen a il1rap y cd3, y usos de estas | |
| UY37683A (es) | Anticuerpo monoclonal anti-pd-l1 monoclonal | |
| MX2018003982A (es) | Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano. | |
| CO2022010244A2 (es) | Anticuerpos anti-e-selectina, composiciones y métodos de uso | |
| AR121129A1 (es) | Anticuerpos anti-e-selectina, composiciones y métodos de uso | |
| AR115987A1 (es) | Anticuerpos anti-gdf15, composiciones y métodos de uso | |
| EA202090586A3 (ru) | Триспецифичные связывающие молекулы и способы их применения |